Third-generation aromatase inhibitors such as anastrozole have proven morebeneficial in suppressing estrogen production in adipose tissue in men than other sources,175 suggesting aromatase inhibition may have additional benefits whenadministered to obese PAH patients. Here, CYP19A1 is linked to pulmonary arterial hypertension.